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Abstract
Introduction—People with serious mental illness experience elevated severe obesity rates, yet 
limited evidence documents whether lifestyle intervention participation can benefit these 
individuals. This study examined the impact of the In SHAPE lifestyle intervention on weight loss 
among participants with serious mental illness and severe obesity (BMI ≥40 kg/m2) compared 
with participants who are overweight (BMI 25 to <30 kg/m2) and have class I (BMI 30 to <35 
kg/m2) or have class II (BMI 35 to <40 kg/m2) obesity.
Methods—Data were combined from three trials of the 12-month In SHAPE intervention for 
individuals with serious mental illness collected between 2007 and 2013 and analyzed in 2014. In 
SHAPE includes individual weekly meetings with a fitness trainer, a gym membership, and 
nutrition education. The primary outcome was weight loss. Secondary outcomes were fitness, 
blood pressure, lipids, and program adherence.
Results—Participants (N=192) were diagnosed with schizophrenia spectrum (53.1%) or mood 
(46.9%) disorders. At 12 months, the overall sample showed significant weight loss, but 
differences among BMI groups were not significant (severe obesity, 2.57% [7.98%]; class II, 
2.26% [8.69%]; class I, 1.05% [6.86%]; overweight, 0.83% [7.62%]). One third of participants 
with severe obesity achieved ≥5% weight loss, which was comparable across groups. More 
participants with severe obesity achieved ≥10% weight loss (20%) than overweight (2.9%, 
p=0.001) and class I (5.9%, p<0.001), but not class II (17.8%, p=0.974), obesity groups.
Conclusions—People with severe obesity and serious mental illness benefit similarly to those in 
lower BMI groups from lifestyle intervention participation.
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Introduction
People with serious mental illness, including schizophrenia, schizoaffective disorder, major 
depressive disorder, and bipolar disorder, experience rates of obesity nearly double the 
observed rates within the general population,1–3 as well as elevated prevalence of severe 
obesity (BMI ≥40 kg/m2).1 This patient population is also disproportionately affected by 
comorbid medical conditions, increased cardiovascular risk, and poor health behaviors, 
which combined with elevated rates of obesity contribute to significantly reduced life 
expectancy up to 30 years fewer than the general population.4,5 This is further exacerbated 
by numerous challenges in achieving weight loss among people with serious mental illness, 
including metabolic effects of psychoactive medications, the impact of symptoms on 
motivation, poor diet, and poverty.2 Lifestyle interventions targeting fitness and diet may be 
an effective approach for addressing this serious public health concern.
In the general population, there is some evidence of the effectiveness and long-term benefit 
of behavioral weight management interventions for individuals with severe obesity.6,7 
Similar behavioral interventions may be well suited for people with serious mental illness 
given recent evidence supporting the use of fitness and diet interventions in this population.8 
For example, studies of different lifestyle interventions have demonstrated effectiveness in 
achieving ≥5% weight loss in upwards of 47% of participants, or reduced cardiovascular 
risk in as many as half of participants with serious mental illness.9–12 However, potential 
differential outcomes in different BMI groups are not known and it is not clear whether 
people with severe obesity and serious mental illness benefit from participation in an 
intensive lifestyle intervention to the same extent as less obese individuals.
The purpose of this study was to examine the impact of the 12-month In SHAPE lifestyle 
intervention on weight loss among participants with serious mental illness who had severe 
obesity (class III) compared with participants who were overweight (BMI 25 to <30 kg/m2) 
and had class I (BMI 30 to <35 kg/m2) or had class II (BMI 35 to <40 kg/m2) obesity. 
Secondary outcomes including fitness, blood pressure, lipids, and program adherence were 
also compared among the different BMI groups. Specifically, the aim of this study was to 
determine whether participants with severe obesity achieved differential outcomes when 
compared with lower BMI classes after participation in the In SHAPE lifestyle intervention.
Methods
The analyses in this study used data from participants who received the In SHAPE lifestyle 
intervention in three separate clinical trials in people with serious mental illness. Two were 
randomized trials and the third was an implementation study. The first randomized trial 
(N=133), conducted from April 2007 to November 2011, compared In SHAPE to gym 
membership at one community mental health center in Concord, New Hampshire.12 The 
second randomized trial (N=210), conducted from April 2008 to May 2013, compared In 
SHAPE to gym membership in people receiving services at one of three community mental 
health centers in Boston, Massachusetts.11 The third evaluation (N=122), conducted 
between December 2009 and March 2013, compared In SHAPE implemented in two 
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community mental health centers with usual care in two additional centers from rural and 
urban settings in New Hampshire.
The current analytic sample consisted of data from the 192 participants who completed the 
12-month In SHAPE intervention. Forty participants completed baseline assessments but did 
not complete the 12-month intervention. These dropouts were not included in the analyses, 
and did not differ from participants who completed the intervention on any baseline 
characteristics.
Participants across all three studies were aged ≥21 years; had serious mental illness defined 
by an axis I diagnosis of major depressive disorder, bipolar disorder, schizoaffective 
disorder, or schizophrenia (based on the Structured Clinical Interview for DSM-IV), and 
persistent impairment in multiple areas of functioning (e.g., work, school, self-care)13; had 
BMI >25 kg/m2; and provided informed consent for participation. Participants were on 
stable pharmacologic treatment defined as receiving the same psychiatric medications over 
the prior 2 months. Detailed inclusion and exclusion criteria are described elsewhere.11,12 
Committees for the Protection of Human Subjects at Dartmouth College and specific to each 
site approved the study procedures.
In SHAPE is a fitness intervention consisting of a gym membership, weekly individual 
meetings with a certified fitness trainer, and instruction on healthy eating and 
nutrition.11,12,14 The fitness trainers completed a 1-week In SHAPE training consisting of 
instruction in motivational interviewing, fitness goal setting, healthy nutrition, tracking 
eating and exercise, and strategies for health behavior change in people with serious mental 
illness such as addressing mental health symptoms that interfere with exercise and healthy 
eating. Prior to enrollment, participants obtained medical clearance from their primary care 
provider. After conducting lifestyle and fitness evaluations, the fitness trainer developed 
personalized fitness plans for each participant using shared goal setting. Thereafter, they met 
with participants individually each week for 45–60 minutes at a local gym (YMCA) and 
provided fitness coaching, support, and reinforcement for exercise. The nutrition component 
consisted of individualized instruction emphasizing healthy eating during each session. 
Throughout the program, the fitness trainers received ongoing supervision from a health 
psychologist, personal fitness trainer, and registered dietitian.
Measures
Assessments were conducted at baseline and at 12-month follow-up for all study outcome 
measures. The primary outcome was weight (pounds) reported as the change in body weight 
over time and as the percentage change in weight. The proportion of participants who 
achieved ≥5% weight loss was calculated because modest weight loss is associated with 
improvements in cardiovascular risk factors in overweight and obese individuals in the 
general population15,16 and with diabetes.17 The proportion of participants who achieved 
≥10% weight loss was also calculated because this widely used metric contributes to well-
documented clinical benefits.18 These measures are considered clinically significant weight 
loss. Additional measures of obesity included BMI, calculated as weight (kg)/height (m)2, 
and waist circumference measured in inches.
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The 6-Minute Walk Test (6-MWT) measures the distance in feet that an individual can walk 
in 6 minutes, and was used to evaluate participants’ fitness. In obese adults in the general 
population, the 6-MWT is considered a reliable and valid measure of fitness.19,20 Change in 
this measure was reported both as a change in feet and as a percentage change in feet. Two 
different measurement criteria for clinically significant improvement in fitness were used. 
First, an increase in distance >50 meters (about 164 feet) on the 6-MWT is considered 
clinically meaningful in terms of reduced cardiovascular risk among people with medical 
conditions including heart failure, chronic obstructive pulmonary disease, and pulmonary 
arterial hypertension.21 Among obese individuals in the general population, a >80 meter 
(about 263 feet) increase is considered clinically significant.19 Therefore, the proportion of 
participants who achieved >80 meter increase on the 6-MWT is reported; however, given 
the numerous challenges in promoting positive lifestyle change and the disproportionate 
burden of chronic disease affecting people with serious mental illness, the broader >50 
meter criteria was also applied.
Blood pressure was measured after completing the 6-MWT. Serum lipids were measured 
using the CardioChek PA Analyzer, a portable testing system that produces reliable values 
for total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein 
cholesterol, and triglycerides using a multipanel test strip and a small amount of blood 
acquired with a finger prick.22 The number of visits, out of a maximum of 50 planned visits, 
with the fitness trainer over the 12-month intervention was measured. Study retention was 
assessed as completing the 12-month assessment.
Data on participants’ current medication use was collected because different antipsychotic 
agents are associated with varying degrees of weight gain23,24 and are known to affect 
ability to lose weight.2 Participants’ antipsychotic medications were classified as high 
weight gain propensity (e.g., olanzapine and clozapine), medium weight gain propensity 
(e.g., risperidone), or low weight gain propensity (e.g., ziprasidone) (footnote in Table 1 
provides a full list of medications).
Statistical Analysis
Participants from different BMI groups were compared at baseline on demographic 
characteristics, obesity measures, fitness, blood pressure, lipids, and use of antipsychotic 
medications and differing weight-gain propensity psychiatric medications using chi-square 
tests for categorical variables and one-way ANOVAs for continuous variables. For 
continuous outcome variables including the primary outcome of weight loss and secondary 
measures of obesity, fitness, blood pressure, and lipids, linear regression models were used 
to compare BMI group means at 12 months, controlling for study (Trial 1, 2, or 3), age, 
gender, race, and program adherence. The proportions of participants in the different BMI 
groups who achieved ≥5% and ≥10% weight loss, and improved fitness (>50- and >80-
meter increase on the 6-MWT) at 12 months were compared via logistic regression models 
adjusting for study (Trial 1, 2, or 3), age, gender, race, and program adherence. When a 
significant association was found between BMI group and an outcome (type III test), post 
hoc pairwise comparisons between BMI groups were performed using contrasts from the 
model. The purpose of these pairwise comparisons was to assess how participants in the 
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class III obesity group differed compared with each of the other groups. For overall 
comparisons between BMI groups, a p-value of 0.05 was considered significant. To assess 
significance of the post hoc pairwise comparisons, a Bonferroni correction was applied to 
the three pairwise comparisons between each BMI group and the class III obesity group. 
Therefore, a p-value of 0.017 (0.05/3) or less was considered significant, yielding an overall 
0.05 significance level for the group of tests. All statistical analyses were performed in 2014 
using SPSS, version 19.
Results
At baseline, marital status, fitness, blood pressure, and high-density lipoprotein cholesterol 
differed among the weight classes (Table 1). Elevated risk of hypertension, defined as 
systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg differed among 
weight classes (p=0.048), and was highest among participants with severe obesity (46.4%). 
Number of antipsychotic medications, use of high weight gain–propensity psychiatric 
medications, smoking status, and other demographic characteristics were comparable among 
BMI groups at baseline. BMI in the severe obesity group ranged from 40.2 to 77.3 kg/m2, 
where 95% had a BMI between 40 and 60 kg/m2.
Table 2 shows the baseline to 12-month changes in the primary outcome of weight, and 
secondary measures including fitness, blood pressure, and lipids. The table presents raw 
unadjusted means for BMI class and p-values from the linear regression models. At 12 
months, the overall sample showed significant weight loss (4.73 [19.20] pounds, p=0.002), 
but differences in weight loss among BMI groups were not significant. Improvement in the 
6-MWT was observed at 12-months for the overall sample (59.89 [228.98] feet, p=0.001), 
with no significant differences among BMI groups. There were no significant differences 
among BMI groups for changes in blood pressure and lipids.
Differences in clinically significant weight loss and improved fitness are illustrated in Figure 
1. The proportions of participants who achieved ≥5% weight loss differed among BMI 
groups (p=0.024). One third (32.7%) of participants with severe obesity achieved ≥5% 
weight loss, which differed significantly compared only with class I (27.5%; p=0.015), and 
not overweight (32.4%, p=0.064) or class II (42.2%, p=0.900), participants. The proportion 
of participants who achieved ≥10% weight loss also differed among BMI groups (p<0.001). 
More participants with severe obesity (20.0%) achieved ≥10% weight loss compared with 
overweight (2.9%, p=0.001) and class I (5.9%, p<0.001), but not class II (17.8%, p=0.974), 
participants.
The proportion of participants who achieved clinically significant improved fitness, based 
on >50-meter increase on the 6-MWT, did not differ among groups (p=0.073). Similarly, the 
proportion of participants who achieved >80-meter increase on the 6-MWT did not differ 
among groups (p=0.080) (Figure 1).
Program adherence differed significantly among BMI groups (p=0.001), with participants 
with severe obesity attending fewer sessions (21.53 [15.43]) compared with overweight 
(27.74 [12.72]), class I (24.49 [14.86]), and class II (29.74 [12.84]) participants. However, 
Naslund et al. Page 5
Am J Prev Med. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
post hoc pairwise comparisons revealed that participants with severe obesity did not differ 
from those in the overweight or class I obesity groups in terms of program adherence, but 
showed significantly lower program adherence compared only with class II participants 
(p=0.009). Study retention did not differ among BMI groups.
Discussion
People with severe obesity and serious mental illness appear to have benefited similarly to 
those in lower BMI groups from participation in a lifestyle intervention targeting fitness and 
weight loss. Not only was percentage weight loss comparable among BMI groups, but 
nearly one third (32.7%) of participants with severe obesity achieved ≥5% weight loss, 
which was higher than class I and comparable to overweight and class II obesity groups. 
Furthermore, one in five participants with severe obesity achieved ≥10% weight loss, 
representing a significantly greater proportion when compared with people in the overweight 
and class I obesity groups, but not those in the class II obesity group.
One quarter of participants with severe obesity achieved improved fitness based on a >50-
meter increase on the 6-MWT, while about 15% achieved improved fitness based on a >80-
meter increase on the 6-MWT, both of which did not differ significantly among BMI 
groups. Despite the smaller number of fitness trainer visits among participants with severe 
obesity, which differed significantly only when compared with participants with class II 
obesity, retention rates in the In SHAPE intervention were comparable across groups. 
Retention among participants with severe obesity was 79.2%, which is consistent with 
retention rates (78%) reported in a weight loss trial of people with severe obesity from the 
general population.25
Modest (≥5%) weight loss and improved fitness are associated with reduction in 
cardiovascular risk,16,21 which is meaningful given the elevated burden of health concerns, 
such as hypertension, diabetes, and metabolic syndrome that disproportionately affect 
people with severe obesity and serious mental illness.1,2,26,27 These positive findings 
associated with reduced cardiovascular risk are also consistent with other evaluations of 
lifestyle interventions targeting people with serious mental illness who are overweight or 
obese.9,10
To the authors’ knowledge, this is the first evaluation comparing the effectiveness of a 
lifestyle intervention among people with serious mental illness who have severe obesity, and 
those who are overweight or have varying levels of obesity. The findings reported here are 
consistent with behavioral weight management interventions in general patient populations. 
For example, in the Look AHEAD (Action for Health in Diabetes) trial, people with severe 
obesity and Type 2 diabetes experienced greater weight loss than people who were 
overweight, and comparable weight loss to people with class I and class II obesity.6 Further, 
in a randomized trial of a diet and physical activity intervention targeting adults with class II 
and class III obesity, people with severe obesity (class III) achieved significantly greater 
weight loss compared with people with class II obesity, and comparable outcomes to people 
with lower levels of obesity from prior lifestyle intervention studies.25 Lastly, in a primary 
care–based weight management program, nearly one third (31%) of people with severe 
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obesity achieved ≥5% weight loss compared with 9% in a usual care control.28 Hence, there 
is mounting evidence that behavioral weight loss approaches can be effective among 
individuals who have severe obesity.
Thirty-one percent of participants in this study had severe obesity, representing a high 
proportion of individuals enrolled in a lifestyle intervention targeting fitness and weight loss 
(prior trials of lifestyle interventions in general patient populations reported that 22%6 and 
17%29 of participants had severe obesity). This suggests that at least a subgroup of people 
with severe obesity and serious mental illness are interested in fitness and weight loss. This 
is consistent with prior findings that individuals with serious mental illness who are obese 
are distressed about their weight and want to lose weight.1,30
Future efforts must capitalize on this interest to lose weight and motivation to enroll in a 
lifestyle intervention among individuals with severe obesity and serious mental illness. Even 
though this study showed comparable outcomes across BMI groups, individuals with severe 
obesity remain at markedly higher risk of cardiovascular disease and other serious health 
concerns. Smoking is also a significant contributor to elevated rates of cardiovascular 
disease and increased mortality among people with serious mental illness.31 The In SHAPE 
intervention did not target smoking, yet 33.9% of participants with severe obesity were 
smokers, highlighting the need to explore lifestyle interventions targeting weight loss, 
fitness, and smoking in this at-risk group.32
Limitations
Several limitations warrant consideration. First, all participants across each of the In SHAPE 
trials were receiving mental health treatment, and therefore these findings cannot generalize 
to individuals with serious mental illness who are not currently in treatment. Second, 70% of 
the sample was non-Hispanic white, which limits generalizability across different minority 
groups. Third, only participants with baseline and 12-month data were included in the 
analyses, which limits generalizability to individuals who completed the study. Even though 
completers and dropouts did not differ on any baseline characteristics, completers may have 
differed owing to unmeasured characteristics. Fourth, the relatively small sample size in 
each of the BMI groups may have increased the risk of Type 2 error. Lastly, long-term 
follow-up data are not available to determine whether outcomes persist equally among BMI 
groups over time. In the Look AHEAD trial, at 4-year follow-up, a significant proportion of 
participants with severe obesity achieved long-term weight loss comparable to other BMI 
groups.7 Future research is necessary to determine whether long-term weight loss can be 
achieved similarly among people with severe obesity and serious mental illness.
Conclusions
Severe obesity is a major public health concern, and it disproportionately affects people with 
serious mental illness. Lifestyle interventions targeting diet and exercise offer valuable 
opportunities for promoting weight loss and reducing cardiovascular risk in this vulnerable 
group, and the current study offers additional strong evidence for implementing these 
programs as part of core services delivered within community mental health settings. 
Targeting people with severe obesity and serious mental illness, a group that is at elevated 
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risk of cardiovascular disease, could help advance ongoing efforts aimed at reducing the 
dramatic life expectancy disparity impacting people with serious mental illness. These 
findings provide strong support for the inclusion of individuals with severe obesity in 
lifestyle interventions targeting fitness and weight loss in people with serious mental illness.
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Figure 1. 
Clinically significant changes in weight and fitness compared between BMI groupsa, b
a
 Overweight: BMI 25 to <30 kg/m2; Class I obesity: BMI 30 to <35 kg/m2; Class II 
obesity: BMI 35 to <40 kg/m2; and Severe Obesity: BMI ≥ 40 kg/m2
b
 The proportion of participants who achieved improved fitness determined as >50 meter 
and >80 meter increase on the 6-Minute Walk Test did not differ significantly between BMI 
groups.
* Participants with class I obesity were significantly less likely to achieve ≥5% weight loss 
compared to participants with severe obesity (OR=0.57; 95% CI=0.37–0.90).
** Participants who were overweight were significantly less likely to achieve ≥10% weight 
loss compared to participants with severe obesity (OR=0.21; 95% CI=0.08–0.52).
*** Participants with class I obesity were significantly less likely to achieve ≥10% weight 
loss compared to participants with severe obesity (OR=0.26; 95% CI=0.13–0.55).
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